Education within the Oura App helps patients understand what to expect in their treatment journey, reducing the uncertainty that too often drives early discontinuation
Due to their cost, however, coverage of GLP-1s for obesity treatment in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, and GLP-1 coverage in Medicare for treatment of obesity is prohibited under current law
SGLT2i were prescribed in a similar manner in the later and earlier periods, although when an SGLT2i was prescribed as an add-on therapy, it was less often added to an ACEi/ARB in the later period than the earlier period (54.0% vs
"We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many." GoodRx replaces a now-defunct partnership between Novo Nordisk and Hims & Hers, which broke down due to what the drugmaker said were concerns about "illegal mass compounding and deceptive marketing." In a statement, GoodRx chief executive Wendy Barnes said that demand for GLP-1 drugs "is at an all-time high, but too many Americans still face barriers accessing them
Patorno, E
